8-K: Foghorn Therapeutics: Oncology Pipeline & Lilly Pact

Foghorn Therapeutics highlights its leadership in chromatin biology, advancing a broad oncology pipeline including a Phase 1 SMARCA2 inhibitor partnered with Lilly and multiple degrader programs.

Summary

• Foghorn Therapeutics is a leader in chromatin biology, focusing on precision therapeutics for challenging oncology targets implicated in up to 50% of all tumors.
• The company has a strategic collaboration with Lilly, established in December 2021, which included a $300 million upfront cash payment and $80 million in Foghorn common stock (at $20 per share).
• The collaboration provides a 50/50 U.S. economic split on the SMARCA2-target (FHD-909) and another undisclosed program, along with tiered ex-U.S. royalties.
• FHD-909 (LY4050784), a selective SMARCA2 inhibitor, is currently in a Phase 1 monotherapy dose escalation trial for advanced solid tumors with SMARCA4 mutations.
• The preclinical pipeline includes selective degraders for SMARCA2, CBP, EP300, and ARID1B, all advancing towards IND-enabling studies or in vivo proof of concept.
• As of September 30, 2025, the company reported $180.3 million in cash and equivalents, projecting a cash runway into 2028.
• Approximately 63.0 million shares were outstanding as of September 30, 2025.
• The company's current pipeline potentially addresses more than 500,000 patients, with chromatin biology having a broad impact across approximately 2.5 million cancer patients.

Sentiment

Score: 8

Explanation: The presentation is highly positive, showcasing a strong pipeline, significant collaboration with a major pharmaceutical company (Lilly), promising preclinical data, and a solid financial position with a long cash runway. The focus on a unique and high-potential area of biology (chromatin regulation) and precision therapeutics adds to the positive outlook.

Positives

• Strategic collaboration with Lilly, a leading oncology company, providing significant upfront funding ($300M cash, $80M stock) and favorable economics (50/50 U.S. split, tiered ex-U.S. royalties) for lead programs.
• FHD-909, a selective SMARCA2 inhibitor, is in Phase 1 clinical development for SMARCA4 mutant cancers, addressing a high unmet medical need population.
• Robust preclinical pipeline featuring multiple selective degrader programs (CBP, EP300, ARID1B) demonstrating promising selectivity and anti-tumor activity in various cancer models.
• Strong financial position with $180.3 million in cash and equivalents as of September 30, 2025, extending the cash runway into 2028.
• Leadership in chromatin biology, a unique and high-potential area of cancer research with implications for up to 50% of all tumors.
• Preclinical data for FHD-909 shows significant anti-tumor activity as monotherapy and in combination with standard therapies (e.g., cisplatin, pemetrexed, KRAS inhibitors, pembrolizumab) in NSCLC models.
• Selective CBP degrader (CBPd-171) demonstrates significant anti-tumor activity in EP300mut solid tumor models and promising potential in ER+ breast cancer, with no significant preclinical heme toxicity.
• Selective EP300 degraders show potent anti-proliferative activity across a broad range of hematological malignancies (e.g., Multiple Myeloma, DLBCL) and prostate models, while sparing platelets.
• The induced proximity platform shows initial proof-of-concept for DUBTACs (protein stabilization) and a novel approach to activate cell death cascades, indicating platform expansion potential.

Risks

• Potential outcomes from the collaboration agreement with Lilly may vary.
• Uncertainty regarding the initiation, timing, progress, and results of research and development programs, preclinical studies, and clinical trials, including the Phase 1 dose escalation trial of FHD-909.
• Challenges in advancing product candidates and successfully completing preclinical and clinical studies.
• Ability to leverage the Gene Traffic Control Platform to develop additional product candidates may be limited.
• Impact of exogenous factors, such_as macroeconomic and geopolitical circumstances, on business operations, including research and development programs and preclinical studies.
• Developments related to competitors and the industry could affect market position.
• Ability to expand target populations of programs and the availability of patients for clinical testing may be constrained.
• Challenges in obtaining regulatory approval for FHD-909 and any future product candidates from the FDA and other regulatory authorities.
• Ability to identify and enter into future license agreements and collaborations may be difficult.
• Reliance on CDMOs and CROs for manufacturing and research needs carries inherent risks.
• Regulatory developments in the United States and foreign countries could impact operations.
• Ability to attract and retain key scientific and management personnel is crucial for success.
• Scope of protection for intellectual property rights covering FHD-909, future products, and the Gene Traffic Control Platform may be insufficient.
• Uncertainty regarding the use of proceeds from capital-raising transactions, estimates of expenses, capital requirements, and needs for additional financing.

Future Outlook

The company anticipates several near-term milestones in 2026, including Phase 1 monotherapy data for FHD-909, IND-ready status for the selective CBP degrader, IND-enabling studies for the selective EP300 degrader, and in vivo proof of concept for the selective ARID1B degrader. Additionally, the selective SMARCA2 degrader and Lilly Target #2 are expected to transition to Lilly for IND. The company projects its cash runway to extend into 2028.

Management Comments

• Foghorn is a Leader in Chromatin Biology, Successfully Drugging Challenging Targets.
• Foghorn's Platform Has Delivered Precision First-in-Class Therapeutics, and is Poised to Unlock New Biology.
• Developing First-in-Class Precision Medicines Targeting Major Unmet Needs in Cancer.

Industry Context

Foghorn Therapeutics operates in the highly competitive oncology sector, focusing on chromatin biology, a complex area implicated in a significant portion of all tumors (up to 50%). Their strategy of targeting previously undruggable targets and leveraging synthetic lethality and lineage dependencies aligns with the broader industry trend towards precision medicine and targeted therapies. The collaboration with Lilly, a leading oncology company, validates their platform and programs, positioning them to compete with other innovative biotech and pharmaceutical firms developing novel cancer treatments, including protein degraders and induced proximity modulators. The company's focus on SMARCA4 mutant NSCLC addresses a high unmet need population, similar to how PARP inhibitors have become a proven clinical approach in other cancers.

Comparison to Industry Standards

• Precision medicine targeting synthetic lethal relationships is a proven clinical approach now used in multiple cancers, with PARP inhibitors cited as an example.
• Preclinical data for the selective CBP degrader (CBPd-59) demonstrates improved tolerability relative to non-selective compounds, showing no significant preclinical heme toxicity, in contrast to dual inhibitors like CCS1477 (Inobrodib) which impacted platelet counts.
• Selective EP300 degraders achieve deeper responses at tolerated doses with no thrombocytopenia, unlike inobrodib whose clinical use is limited by thrombocytopenia requiring dosing holidays.
• Foghorn's analysis and Dmax results for SMARCA2 degraders are stated to match published data from Prelude (PRT3789 (VHL) and PRT7732 (CRBN)), indicating their ability to replicate and understand industry benchmarks in degrader efficiency.

Stakeholder Impact

• Shareholders: Potential for increased value due to pipeline advancement, strong collaboration, and extended cash runway. The company's focus on high-unmet-need cancers could lead to significant market opportunities.
• Patients: Potential for novel, precision therapies for various cancers, especially SMARCA4-mutant NSCLC and other genetically defined tumors.
• Employees: Continued employment and potential growth opportunities within a company with a robust pipeline and strong financial backing.
• Lilly (Partner): Continued collaboration on promising oncology programs, potentially leading to new drug approvals and market share.

Next Steps

• Phase 1 Monotherapy Data for FHD-909 (LY4050784) in 2026.
• IND-ready for Selective CBP Degrader in 2026.
• IND-enabling Studies for Selective EP300 Degrader in 2026.
• In Vivo Proof of Concept for Selective ARID1B Degrader in 2026.
• Transition of Selective SMARCA2 Degrader to Lilly for IND.
• Transition of Lilly Target #2 to Lilly for IND (pending Lilly decision).
• CBPd-171 in DRF studies in Q4 2025.
• LAI characterization in additional pharmacology studies planned to refine human dose predictions for CBPd-171.

Key Dates

Recommendation

The filing presents a compelling investment case. The company has a strong strategic partnership with Lilly, validating its platform and providing substantial non-dilutive funding. The pipeline, particularly the clinical-stage FHD-909 and multiple preclinical degrader programs, targets large, unmet needs in oncology with a differentiated approach (chromatin biology). The robust preclinical data, clear near-term milestones, and a cash runway into 2028 significantly de-risk the investment, suggesting strong potential for future value creation.

Keywords

Chromatin Biology, Oncology, Precision Therapeutics, Protein Degraders, SMARCA2 Inhibitor, FHD-909, Lilly Collaboration, SMARCA4 Mutant Cancers, NSCLC, CBP Degrader, EP300 Degrader, ARID1B Degrader, Gene Traffic Control Platform, Biotechnology, Cancer Treatment